US equities |
MU $927.80 ▼-2.66% NVDA $222.09 ▼-2.81% AAPL $344.48 ▲+0.94% META $738.90 ▼-3.10% AMD $572.71 ▼-5.42% TSLA $366.34 ▼-2.37% SPCX $153.30 ▼-2.07% SNDK $1,421.38 ▼-4.11%
FinancialContent

Nanobiotix S.A. - ADSs (NQ:NBTX)

21.47 -0.02 (-0.09%)
Delayed Quote Updated: 12:40 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 7 Next >
News headline image
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides First Half 2026 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Joins the Euronext Tech Leaders Index
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Closing of Global Offering
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Launch of Global Follow-On Offering
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Statement Regarding Recent Media Speculation
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Investor Conferences in March
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >